



NEWS RELEASE

CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

2024-04-19

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx’s common stock (the “Inducement Option”) and 487,804 restricted stock units (the “Inducement RSUs”) to John Hanna, CareDx’s newly appointed President and Chief Executive Officer. The Inducement Option and the Inducement RSUs were approved by the Compensation and Human Capital Committee of CareDx’s board of directors on March 25, 2024, and were an inducement material to Mr. Hanna’s employment with CareDx in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Option has an exercise price of \$8.20 and will vest over four years, with 25% of the total number of shares subject to the Inducement Option vesting on April 15, 2025, the one-year anniversary of the date of commencement of Hanna’s employment with CareDx, and 1/48th of the total number of shares subject to the Inducement Option vesting at the end of each calendar month thereafter, subject in each case to Hanna’s continued services with CareDx on each vesting date. The Inducement RSUs will vest in four equal, annual installments beginning on April 15, 2025, the one-year anniversary of the date of commencement of Hanna’s employment with CareDx, subject in each case to Hanna’s continued services with CareDx on each vesting date.

CareDx is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on



the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward-Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the equity grants. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors; and other risks discussed in CareDx's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CareDx, Inc.

Media Relations

Anna Czene

818-731-2203

[aczene@caredx.com](mailto:aczene@ caredx.com)

Investor Relations

Greg Chodaczek

investor@caredx.com

Source: CareDx, Inc.